To strengthen the nation’s public health, different regulatory authorities are working that not only provide guidelines for drug marketing but also enforce the rule and regulations. The drug approval process is a protracted and tedious process requiring much data, but the scenario changes during a pandemic, or epidemic when any type of nuclear, radiological, biological, or chemical, an emergency occurs. During such situations regulatory bodies authorizes unapproved drugs based on certain parameters in the context of public health. To counteract these situations regulatory authorities worldwide expedited the approval process and set up the guidelines or pathways for unapproved drugs, which can be a game changer in life-threatening or serious conditions.
CORONAVIRUS (COVID-19) PANDEMIC
In late December 2019, the first case of the virus was found in Wuhan, Hubei Province, China, and spread fast worldwide in a short period. The culprit behind this COVID-19 is a highly contagious disease caused by severe acute respiratory syndrome coronavirus-2. During the corona pandemic, the complete and partial lockdown was imposed worldwide that adversely affected not only the health-related quality of life, socioeconomic status, education, farming, and industry but also the country’s economy as manufacturing, supply chain, transportation, and distribution of products and services was hampered. This virus had a disastrous effect on the world’s sociodemographics that lead to more than 3.5 million deaths worldwide. Hence, on March 11, 2020, the World Health Organization (WHO) declare it a global pandemic, according to the report of a worldometer worldwide.
Hence, here we will not only compare the emergency use authorization (EUA) procedure among the United States Food and Drug Administration (USFDA), European Union (EU), and India but we will also look into the history of such category drugs with their pro and cones.
EMERGENCY USE AUTHORIZATION – UNITED STATES FOOD AND DRUG ADMINISTRATION
The USFDA commissioner has sovereignty over for the issuance of the EUA, but after considering and consulting the prevalent conditions and indications with the secretaries of different departments as the case may be. The emergency may be categorized as military, domestic, public health, or related to a material threat. Depending on the area or sector concerned, the respective secretary is approached and a decision over EUA is taken while considering the Federal Food, Drug, and Cosmetic Act, section 564 as shown in Figure 1. Different departments and secretaries under USFDA are:
- The Department of Defence (DoD): At the time of a military emergency or striking risk the military DoD secretary issues a declaration of EUA
- The Department of Homeland Security (DHS): Whenever there is an internal emergency or exceptional risk of a domestic emergency, the DHS secretary will issue a declaration like a material threat declaration
- The Department of Health and Human Services (HHS): At the time of any potential risk or public health emergency (PHE) the secretary of HHS will issue a declaration
- The DHS secretary releases a material threat determination.
The Food and Drug Administration (FDA) commissioner consult with the HHS, the Center for Disease Control and Prevention, the Assistant Secretary for Preparedness and Response, and the National Institutes of Health, before providing the EUA, if the criteria are met. The FDA publishes all information about EUA for public awareness in the federal register.[3,4] To avoid and overcome such emergency situations, when no suitable, approved alternatives are available, the use of either unapproved medical products or approved medical product’s unapproved uses also known as drug repurposing are allowed to use in serious or life-threatening diseases or conditions.
Criteria and conditions for emergency use authorization
The process of EUA is expedited based on different evidence of preclinical, clinical studies, and trials while considering its efficiency, efficacy, intended use, and benefit-risk outweigh ratio. The normal marketing approval process is comparatively long.
- EUA strictly required physicians and hospitals to keep records of the allocation and dispensing of such drugs specifying each and every piece of information, like how to use the product, whom will be administered and through which route, and in what amount with the frequency of dosing
- EUA follows the firm labeling restrictions that not allowed to mention or suggest that the drug is effective and safe for the current emergency as lacking thorough study in highly complex conditions, comorbidities, and pregnant women, so used only under the terms of the EUA-FDA
- The informed consent form is an important part of the EUA as it is considered a fact sheets of the product, shared with patients by the health-care professionals
- MedWatch reporting system of the FDA allows clinicians to report any medication error and serious adverse events associated with the said drug immediately.
Such type of EUA is valid on the basis of certain statutory criteria, up to the circumstances that justify it or when the US government declares so. The EUA authority of the USFDA allows for facilitating the availability of medicinal product and medical countermeasures during any pandemic or PHE, few examples are shown in Table 1.
The public health services act, section 319 covers the law for PHE. During COVID-19, the HHS secretary declared the emergency on February 4, 2020, by observing the significant potential risk of PHE that not only affect national security but also the health and security of the US people living in other countries. If appropriate and needed, the FDA can terminate the declaration and EUA. In such postemergency situations, drugs and biologics approved by the emergency pathway cannot be used and the applicant needs to follow the standard drug approval pathway of the USFDA which is like filling of Investigational New Drug Application (IND) and New Drug Applications (NDA).
CONDITIONAL MARKETING AUTHORIZATION – EUROPEAN UNION
In EU, there are 27 countries but for the approval of medicinal product their regulatory authority European Medicines Agency (EMA) works with scientific committees such as Committee for Medicinal Product for Human Use (CHMP) and Pharmacovigilance Risk Assessment Committee. They together work for the approval of medicinal products with special emphasis on safety and risk minimization, and accelerated procedures of marketing authorization known as conditional marketing authorization. Such procedure support research and development by evaluating medicines, biologics (vaccines), and treatments not only for COVID-19 but for other emergencies also. The rapid approval process of EU has four steps, as shown in Figure 2:
- The rolling reviews
- Application submitted for conditional marketing authorization (CMA)
- Procedure review by EMA’s scientific committee
- Approval discussion by EMA on whether to grant CMA or not.
Whenever there is any PHE, EMA starts evaluating clinical data as soon as possible for the promising medicine as the clinical data continue to emerge EMA needs to conduct several rolling review cycles. Once the entire clinical data are available and are verified and reviewed for the quality, safety, and efficacy of the drug after then the company/sponsor can formally apply for marketing authorization application (MAA) to the EMA. CMA plays an important role during public health emergencies to save lives as it speedily approves the medicine/biologic so known as fast-track authorization. PHE or pandemic may emerge due to severely contagious or life-endangered diseases. CMA is accepted when the available data of the treatment shows benefits outweigh its risks, in such conditions with less comprehensive data (pharmaceutical and nonclinical data) market authorization is approved to address the unmet medical needs of patients. In such conditions, the applicant will provide the all required comprehensive clinical data as per the general approval process in the future.
Criteria and Conditions for conditional marketing authorization
If medicine fulfilled all of the following criteria then CMA is granted to the sponsor:
- The benefit-to-risk ratio, of medicine must be positive
- In the future postauthorization, whether the applicant would be in a position to provide comprehensive clinical data or not
- Unmet the medical need of the patients must be fulfilled by the medicine
- If the medicine’s immediate availability to patients is more beneficial than the risk of not providing additional data.
Such medicine/biologics approved under CMA, initially remain valid for only 1 year and can be renewed annually. Once the CMA is granted, to convert it into standard centralized MAAs, the marketing authorization holder, must fulfill the obligation imposed by the EMA within the defined timeline. These obligations are required to prove that the benefit–risk ratio of the medicine/biologics still remains positive after analyzing the additional compiled data of all pending trials and research. EMA timely publishes the list of medicine/biologics in the European public assessment report, to which the CMA is granted. In an emergency situation, when CMA is provided to the sponsor without any specific obligations for 5 years, it can be reviewed against a standard marketing authorization and renewed for unlimited validity. EMA can take regulatory action either by suspending or revoking the marketing authorization if the new data of any medicine/biologic’s benefits no longer outweigh its risks or if the company or sponsor does not comply with the obligation imposed by the regulatory authority. During the COVID-19 pandemic, this fast track authorization pathway or CMA was widely used to grant access to safe and effective COVID-19 vaccines to all EU citizens simultaneously and to support mass vaccination campaigns as shown in Table 1.
Guidance for applicants for conditional marketing authorization
For speedy submission, and to figure out necessary steps and documents EMA advises applicants to arrange a presubmission meetings with scientific advice or protocol assistance to discuss their development plans. It helps them to understand the development of medicine/biologics, and whether CMA will be granted to them or not. The applicant must indicate in their notification as well as the request of CMA, about the submission of MAA. Applicant can submit their request 6 to 7 months before submitting the application. Under exceptional circumstances of authorization, unlike CMA the applicant need not to provide the comprehensive data postauthorization.
INDIA: RESTRICTED USE IN EMERGENCY
Central Drug Standard Control Organization (CDSCO), the regulatory authority in India takes care of all the approval processes. To address novel pandemics or public health emergencies were taken care of by the Ministry of Home Affairs through the National Disaster Management Act of 2005 and the Ministry of Health and Family Welfare through the Epidemic Diseases Act of 1897 like USFDA regulation. We initially does not have expedited pathway to respond to PHE, India’s first time formalized accelerated approval pathway came into effect in the form of New Drugs and Clinical Trials (NDCT) rules 2019, under the Drugs and Cosmetic Act 1940 and Rules 1945 by CDSCO.[12,13]
In view of the COVID-19 surge in India, by keeping the suspension rules 81 and 83 of the NDCT act 2015 Rules, 2019 regulator allowed “Accelerated Approval Process” permission for a few drugs and also issue a formal notification for the manufacture of novel vaccines. In the same context, on April 11, 2021, the National Expert Group on vaccination for COVID-19 decided that the if foreign produced vaccine for COVID-19 was already approved by USFDA, EMA, United Kingdom’s Medical and Healthcare Products Regulatory Agency (UKMHRA), Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for restricted use, and any drug that is WHO listed for emergency use, then Drug Controller General of India (DCGI) will issue permission for the same as shown in Table 1.
Condition supporting restricted emergency use
- All the vaccine which gets authorized shall follow the guidelines mentioned under COVID-19 vaccination programs
- The first 100 recipients vaccine shall be assessed for 7 days to evaluate their safety before they launch the vaccination program
- The applicant shall initiate a clinical trial within 30 days of such approval.
Procedures for approval of COVID-19 vaccine under restricted emergency use
- Submission of application: Application shall be made as per the Drug and Cosmetics Act 1940 by the foreign manufacturer through its Indian subservient or authorized agent in India
- The application can be submitted via “SUGAM” portal online along with stipulate fees and common technical document (CTD).
- Applicants can also submit registration certificate application and import license application along with the Restricted emergency use (REU) application as shown in Figure 4.
- Processing of application: CDSCO will evaluate such application at the highest priority through the accelerated review process if required will guide on such matters for the regulatory pathway, and DCGI will consider the application and made a decision whether to grant REU or not within three working days from the REU application submission date
- CDSCO after REU application approval, evaluate the registration certificate and import license applications submitted by the applicant and make the decision within three working days after the approval of the vaccine
- Once the import license is granted, according to the CDSCO, the current protocol before using vaccine as per the vaccination program applicant needs to get every imported batch of vaccine must be tested at Central Drug Laboratory, Kasauli
- The safety data submitted by the applicant will be reviewed by CDSCO and once found satisfactory, will authorize the applicant to use the vaccine under the COVID-19 vaccination program as shown in Figure 3.[16,17]
The concluding comparison of all three processes, namely, USFDA, EMA, and CDSCO’s with their applicable criteria and conditions with their limitations or end of these temporary measures are discussed in tabular form as follows in Table 2.[18,19]
During the “PHE” COVID-19, precaution and administration of vaccine significantly reduced the number of COVID-19 patients worldwide. Despite the fact of the immediate requirement of the vaccine to control the crisis, we cannot forget that the vaccine must be safe and effective for human use. The WHO along with the regulatory authority has taken several step to ensure the availability of medicine/biologics worldwide. Regulatory authorities adopted “Emergency use authorization pathways” to approve medicinal products/biologics on the basis of outweigh benefit–risk ratio after ensuring their proper safety and quality in different clinical trials. Despite all these expedited processes, we consider it an ethical dilemma for regulatory agencies to compromise with the actual approval process to deal with unmet medical needs in which they are not 100% sure about product safety, efficacy, and quality. Product approved by these pathways with the objective to ultimately reduce the approval time during PHE-like COVID-19 and under other certain conditions.
In the Indian context, there is a need for not only well-drafted, transparent, authentic decision-making procedures based on the prevalent conditions, but also bolstered research of academicians, legitimization of the company’s claim on its drug product, helped health-care professional to access evidence pertaining to their medical practice.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
1. COVID-19 Coronavirus Pandemic Cases Updates. Dover. Delaware, U.S.A. 2022. Available from: http://Worldometers.info.
. [Last accessed on 2022 Jul 25]
2. Vishal P, Rahulgiri G, Pratik M, Kumar BJ. A review on drug approval process for US, Europe and India. Int J Drug Regul Aff 2014;2:1-11
3. Patel VJ, Patel DM. A comprehensive review on registration requirements for drug approval in India, South Africa and US. Int J Drug Regul Aff 2021;9:62-71
5. Martinez D, Talbert T, Romero-Steiner S, Kosmos C, Redd S. Evolution of the public health preparedness and response capability standards to support public health emergency management practices and processes. Health Secur 2019;17:430-8
6. Zuckerman DM. Emergency use authorizations (EUAs) versus FDA approval:Implications for COVID-19 and public health. Am J Public Health 2021;111:1065-9
7. Hidalgo-Simon A, Botgros R, Cochino E. Authorization of vaccines
in the European Union. Mol Front J 2021;5:58-65
8. Cavaleri M, Enzmann H, Straus S, Cooke E. The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
. Lancet 2021;397:355-7
10. The Epidemic Diseases Act 1897. 2019. Available from: https://legislative.gov.in/year-of-enactment
. [Last accessed on 2022 Jun 25]
11. The Disaster Management Act 2005. 2022. Available from: https://ndma.gov.in/about-us/introduction
. [Last accessed on 2022 Jun 25]
12. New Drugs and Clinical Trials Rules; 2019 G.S.R 227(E). 2022. Available from: https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/
. [Last accessed on 2022 Jun 25]
13. CDSCO Nd-A-ib. Guidance for Approval COVID-19 Vaccines
in India for Restricted Use in Emergency Situation Which are Already Approved for Restricted Use by US FDA, EMA, UK MHRA, PMDA Japan or Which are Listed in WHO Emergency Use Listing (EUL). 2021. Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/notice15april21.pdf
. [Last accessed on 2022 Nov 26]
14. Bhave AC. Indian regulatory update during the COVID-19 pandemic. Perspect Clin Res 2020;11:132-4
15. Dinda AK, Tripathi SK, John B. Revisiting regulatory framework in India for accelerated vaccine development in pandemics with an evidence-based fast-tracking strategy. Indian J Med Res 2020;152:156-63
16. CDSCO. Details of Approved COVID-19 Vaccines
in the Country. 2022. Available from: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NzY2OQ==
. [Last accessed on 2022 Jun 17]
17. Ministry of Health and Family Welfare, editor. Union Health Ministry Issues Regulatory Pathways for Foreign Produced COVID-19 Vaccines
. PIB Delhi: HFW-COVID-Vaccines
Regulatory Pathway; 2021
18. Dias RS. Critical analysis of the worldwide regulatory tools for expedited marketing authorization. Faculty of Pharmacy, University of Lisbon 2021
19. Saint-Raymond A, Sato J, Kishioka Y, Teixeira T, Hasslboeck C, Kweder SL. Remdesivir emergency approvals:A comparison of the U.S., Japanese, and EU systems. Expert Rev Clin Pharmacol 2020;13:1095-101